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Background: Several studies suggested that vaccines could have non-specific effects on mortality depending on
the type of vaccine. Non-specific effects seem to be different in boys and girls. In this study we want to investigate
whether there are differences in gender-specific mortality among Dutch children according to the last vaccination
received. We tested the hypothesis that the mortality rate ratio for girls versus boys is more favourable for girls
following MMR ±MenC vaccination (from 14 months of age) compared with the ratio following DTP-IPV vaccination
(2–13 months of age). Secondarily, we investigated whether there were gender-specific changes in mortality following
booster vaccination at 4 years of age.
Methods: This observational study included all Dutch children aged 0–11 years from 2000 until 2011. Age groups were
classified according to the last vaccination offered. The mortality rates for all natural causes of death were calculated by
gender and age group. Incidence rate ratios (IRRs) were computed using a multivariable Poisson analysis to compare
mortality in boys and girls across different age groups.
Results: The study population consisted of 6,261,472 children. During the study period, 14,038 children (0.22%) died,
91% of which were attributed to a known natural cause of death. The mortality rate for natural causes was higher
among boys than girls in all age groups. Adjusted IRRs for girls compared with boys ranged between 0.81 (95% CI 0.74-
0.89) and 0.91 (95% CI 0.77-1.07) over the age groups. The IRR did not significantly differ between all vaccine-related
age groups (p = 0.723), between children 2–13 months (following DTP-IPV vaccination) and 14 months - 3 years
(following MMR ±MenC vaccination) (p = 0.493) and between children 14 months - 3 years and 4–8 years old (following
DTP-IPV vaccination) (p = 0.868).
Conclusions: In the Netherlands, a high income country, no differences in gender-specific mortality related to the type
of last vaccination received were observed in DTP-IPV- and MMR ±MenC eligible age groups. The inability to detect this
effect indicates that when non-specific effects were present the effects were not reflected in changes in the differences
in mortality between boys and girls. The findings in this large population-based study are reassuring for the continued
trust in the safety of the national vaccination programme.
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The Dutch National Immunisation Programme (NIP)
has contributed greatly to reduced mortality among in-
fants and (young) children. Since its introduction in
1957, the number of deaths due to diseases targeted by
the NIP has drastically declined [1]. Notwithstanding
this important contribution of vaccinations, several stud-
ies in recent decades have suggested that vaccinations
could also give non-specific effects, i.e. effects on non-
targeted diseases, on mortality, with differential effects
in boys and girls [2-17]. It is therefore of great public
health relevance to explore the overall impact of vaccin-
ation on mortality.
Studies in countries with high childhood mortality
observed that live attenuated vaccines, such as the
measles vaccine and BCG-vaccine, might reduce mor-
tality far more than can be attributed to the target
disease [2,3,7,8,10,12-16]. In contrast, it has been sug-
gested that inactivated vaccines, such as DTP, can in-
crease the mortality from infections other than the
target disease [2-8,10,11,13-17]. Such non-specific ef-
fects can be significant, with changes in all-cause mor-
tality of more than fifty percent. Both positive and
negative effects were stronger in girls than in boys
[2,3,5,6,9,10,13-17]. Several mechanisms driving poten-
tial sex-differential effects of vaccines have been sug-
gested, including differences in adaptive and innate
immunity [2,18].
In the Netherlands, no research has been performed
to date on possible non-specific effects of vaccination on
mortality. However, such potential effects of vaccina-
tions need to be explored proactively for public health
purposes to guide vaccination policy, including ensuring
accurate information to the public and maintaining pub-
lic trust in public health interventions such as vaccina-
tions. To assess whether there are such non-specific
effects of vaccines, mortality in vaccinated and unvac-
cinated children should be compared, ideally in a rando-
mised controlled trial. However, the use of randomised
controlled trials is not feasible or ethical in this case, as
the direct benefits of vaccination have been demon-
strated very convincingly. In the Netherlands, vaccin-
ation coverage is high, and childhood mortality is low.
Therefore, in this study, we retrospectively investigated
whether there were indications for differences in gender-
specific mortality among children with respect to the
ages of last vaccination offered. We hypothesized that
the mortality rate ratio for girls versus boys is more
favourable for girls following MMR ±MenC vaccination
(after 14 months of age) compared with the ratio after
DTP-IPV vaccination (2–14 months of age). Secondary
we investigated whether there are gender-specific changes
in mortality following booster vaccination at 4 years of
age.Methods
Study design and population
For this observational study, a dynamic cohort was used
that included all Dutch children who were 0-11-years-
old in the years 2000 to 2011. The date of study entry
was 01/01/2000 or the date of birth, whatever was last.
The end date of follow up was 31/12/2011, the date of
12th birthday or the date of death, whatever came first.
The data were available from Statistics Netherlands, who
linked demographic data of persons included in the Mu-
nicipal Personal Records Database (GBA) with causes of
death derived from Statistics Netherlands.
Dutch national immunisation programme
The Dutch NIP was started in 1957 with childhood vac-
cinations against diphtheria, tetanus, pertussis and polio-
myelitis. The programme has been regularly updated
and modified ever since its inception. The current
programme contains childhood vaccinations against
diphtheria, tetanus, pertussis, polio, Haemophilus influ-
enzae serotype b, mumps, measles, rubella, meningococ-
cal serogroup C (MenC), hepatitis B, pneumococcal
disease and human papillomavirus (Table 1). Table 2
presents the main changes in the childhood NIP
programme in the period 1988 to 2011. Some of the im-
portant changes are the introduction of meningococcal
C vaccination in 2002 at 14 months of age (i.e., adminis-
tered together with the MMR vaccine) with in addition a
catch-up campaign up to 19 years of age, the expansion
of the DTP-IPV vaccine with Haemophilus infuenzae
type b and hepatitis b components in 2003 and 2011, re-
spectively, and the introduction of pneumococcal vaccin-
ation in 2006 at 2, 3, 4 and 11 months of age
(simultaneous with DTP-IPV/Hib).
For many years, the childhood vaccination coverage
has been high (92-96%; measured at the age of 2 years
for newborns, at the age of 5 years for toddlers and at
the age of 10 years for schoolchildren [19]) for all target
diseases (Table 1), except for HPV, resulting in an highly
effective NIP [1]. Therefore, in this study, we assumed
all children to be vaccinated according to the Dutch
schedule. In addition to the NIP, children with parents
originating from tuberculosis endemic countries are
invited for vaccination with Bacillus Calmette-Guérin
(BCG) vaccine.
Absolute contraindications for vaccination are a proven
serious allergy for one of the components of the vaccine
or a proven serious allergic reaction following the admin-
istration of the same vaccine. Relative contraindications,
in which the administration of the vaccine should be con-
sidered, include cases of fever (≥38.5 C) and serious im-
mune disorders (disease, treatment with corticosteroids
or cytostatics, radiation), following the administration of
blood products or immunoglobulins, and patients with
Table 1 Vaccination scheme and coverage of the Dutch NIP in 2011
Age Vaccination 1 Coverage vaccine 1 (%) Vaccination 2 Coverage vaccine 2 (%)
2 months DTaP-HBV-IPV/Hib Pneumo
3 months DTaP-HBV-IPV/Hib Pneumo
4 months DTaP-HBV-IPV/Hib Pneumo
11 months DTaP-HBV-IPV/Hib 95.4/96.0 Pneumo 94.8
14 months MMR 95.9 MenC 95.9
4 years DTaP-IPV 92.0
9 years DT-IPV 92.2 MMR 92.1
12 years HPV (3 doses)* 52.5
*Only for girls; three doses on 0 days, 1 month and 6 months.
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nancy, or planned anaesthesia. However, these cases are
quite rare, i.e., 5–1000 cases per year.
Analysis
The following age groups were created: 0–1 months
(i.e., unvaccinated), 2–13 months (i.e., following DT(a)
P(−HBV)-IPV(/Hib) (and pneumococcal) vaccination),
14 months to 3 years (i.e., following MMR (and men-
ingococcal C) vaccination (Figure 1)), 4–8 years (i.e.,
following DT(aP)-IPV booster vaccination) and 9–11
years (i.e., following DT-IPV booster and MMR booster
vaccination).Table 2 Major changes in the Dutch NIP from 1988 to 2011
Month/Year Change
July 1993 Introduction of vaccination against Haemophilus influ
January 1999 Advanced age for start of primary vaccinations from
July 2001 Acellular pertussis vaccine added at 4 years of age fo
September 2002 Meningococcal serogroup C vaccine added at 14 mo
campaign for everyone up to the age of 19 years
March 2003 Hepatitis B vaccination added for infants in specified
1st January 2003
Haemophilus influenza serotype b vaccine given with
born on or after 1st April 2002
January 2005 Whole cell pertussis component of the DTwP-IPV vac
11 months of age for all children born after the 1st Fe
January 2006 Hepatitis B vaccination added at birth for children of
June 2006 Pneumococcal vaccination added at 2, 3, 4, and 11 m
Introduction of combined vaccine DTaP-HBV-IPV/Hib
born on or after 1st April 2006
July/August 2006 Transition to combined DTaP-IPV vaccine for children
January 2008 Hepatitis B vaccination added for children with Down
March 2009 Human papillomavirus (HPV) catch-up campaign for g
January 2010 HPV vaccination for 12-year-old girls born on or after
March 2011 The 7-valent pneumococcal vaccine was replaced by
1st March 2011
August 2011 Hepatitis B vaccination introduced for all children borMortality rates and 95% confidence intervals for all
natural causes of death, which was defined as all causes
of death other than unknown and external causes of in-
jury and poisoning, were calculated by gender and by
age group. Children who died from unknown causes or
external causes of injury and poisoning were censored in
the analyses. Crude monthly incidence rate ratios (IRR)
for girls compared to boys were visualised. IRR, with ac-
companying 95% confidence intervals, by age group for
girls compared with boys were computed using multi-
variable Poisson regression adjusted for calendar year.
To assess whether the IRR differed between age groups,
the interaction between age group and gender was testedenzae type b (Hib) disease for all children born on or after 1st April 1993
3 to 2 months
r all children born on or after 1st January 1998
nths of age for all children born on or after 1st June 2001 and a catch-up
risk groups at 2, 4, and 11 months of age for all children born on or after
the DTwP-IPV vaccine at 2, 3, 4, and 11 months of age for all children
cine was replaced by the acellular pertussis component at 2, 3, 4, and
bruary 2004
mothers who tested positive for HBsAg
onths of age for children born on or after 1st April 2006
at 2, 3, 4, and 11 months of age for children in specified risk groups
at 4 years of age born from July/August 2002 onwards
syndrome born on or after 1st January 2008
irls born 1993-1996
1st January 1997
the 10-valent pneumococcal vaccine for children born on or after
n on or after 1st August 2011
Figure 1 Lexis diagram of the analysed cohort. Diagram that represents the type of last vaccination received for the analysed cohort by age
and year. The bold vertical lines represent the study period and the dashed vertical line represents the introduction of Meningococcal C
vaccination. All changes in the vaccination schedule are presented in Table 2.
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interaction for both hypotheses specifically (df = 1), i.e. for
14 months – 3 years of age versus 2–13 months of age
and for 4–8 years of age versus 14 months – 3 years of
age. In addition, we conducted several sensitivity analyses:
1) including only the indigenous Dutch population, as de-
fined by Statistics Netherlands as children of whom both
parents were born in the Netherlands; 2) comparing the
periods before and from September 2002 onwards, i.e. be-
fore and after the introduction of vaccination against
meningococcal C at 14 months of age; 3) including only
natural causes of death other than complications of preg-
nancy, childbirth and the puerperium, conditions originat-
ing in the perinatal period and congenital abnormalities;
4) including only infectious and parasitic diseases.
Ethical statement
The data were made available by Statistics Netherlands.
The provided data was fully anonymised. Due to this,




The total study population consisted of 6,261,472 indi-
vidual children, accounting for 30,023,460 person-years.
During the study period, 14,038 children (0.22%; mortal-
ity rate 4.7/10,000 person years) died. For approximately
9% of the deceased children, an unknown or non-natural
cause of death was recorded (Table 3), and these chil-
dren were censored in the analysis.Mortality rates
The mortality rate due to natural causes was highest for
children 0 to 1 months old. This high mortality rate was
mainly caused by the relatively high mortality during the
first day after birth, which accounted for 25% of all
childhood mortality occurring in the first month of life.
In all age groups, the mortality rate was higher among
boys than girls (Table 4). Mortality rates declined over
the years from 2000 to 2011 (for boys 4.0 in 2000 to 2.8
in 2011; for girls 3.4 in 2000 to 2.1 in 2011).
The plot of female-to-male IRR shows that IRR fluctu-
ated over age in months, however, intervals were overlap-
ping (Figure 2). IRRs fluctuated over the years, especially
for children 9–11 years of age (data not shown). The ad-
justed IRRs for girls compared with boys ranged between
0.81 (95% CI 0.74-0.89) and 0.91 (95% CI 0.77-1.07) in the
age groups (Table 4). In particular, the IRR for children 2
to 13 months-old was 0.81 (95% CI 0.74-0.89) and for
children 14 months-old to 3 years-old the IRR was 0.85
(95% CI 0.76-0.95). Importantly, no statistically significant
differences in IRRs were observed between all age groups
(p = 0.723), between children 2–13 months and 14 months -
3 years (p = 0.493) and between children 14 months -
3 years and 4–8 years old (p = 0.868). In sensitivity
analyses for indigenous Dutch children only, for periods
before and from September 2002 onwards, for natural
causes of death other than complications of pregnancy,
childbirth, perinatal period and congenital abnormalities,
and for infectious and parasitic diseases only, no statisti-
cally significant differences in IRR between vaccine-related
age groups were found (Table 5).
Table 3 Characteristics of the study population
Characteristic Boys Girls Total
n (%) n (%) N (%)
Population 0–11 yr 3,188,004 3,073,468 6,261,472
Indigenous Dutch 2,292,021 (71.9) 2,189,282 (71.2) 4,481,303 (71.6)
1st generation immigrant 306,934 (9.6) 322,167 (10.5) 629,101 (10.0)
2nd generation immigrant 589,049 (18.5) 562,019 (18.3) 1,151,068 (18.4)
Deaths 7,924 6,114 14,038
0-1 monthsa 4,713 (59.9) 3,688 (60.3) 8,401 (59.8)
2-13 monthsb 1,143 (14.4) 870 (14.2) 2,013 (14.3)
14 months – 3 yearsc 902 (11.4) 671 (11.0) 1,573 (11.2)
4-8 yearsd 766 (9.7) 557 (9.1) 1,323 (9.4)
9-11 yearse 400 (5.0) 328 (5.4) 728 (5.2)
Primary cause of death
Unknown 128 (1.6) 122 (2.0) 250 (1.8)
Infectious and parasitic diseases 203 (2.6) 171 (2.8) 374 (2.7)
Neoplasms 512 (6.5) 393 (6.4) 905 (6.4)
Diseases of the blood and blood forming organs and certain disorders involving the
immune mechanism
53 (0.7) 46 (0.8) 99 (0.7)
Endocrine, nutritional and metabolic diseases 196 (2.5) 148 (2.4) 344 (2.5)
Mental and behavioural disorders 23 (0.3) 19 (0.3) 42 (0.3)
Diseases of the nervous system 383 (4.8) 337 (5.5) 720 (5.1)
Diseases of the circulatory system 176 (2.2) 134 (2.2) 310 (2.2)
Diseases of the respiratory system 162 (2.0) 125 (2.0) 287 (2.0)
Diseases of the digestive system and the genitourinary system 99 (1.2) 61 (1.0) 160 (1.1)
Diseases of the skin, subcutaneous tissue, musculoskeletal system and connective tissue 13 (0.2) 17 (0.3) 30 (0.2)
Complications of the pregnancy, childbirth and the puerperium and conditions
originating in the perinatal period
2,973 (37.5) 2,192 (35.9) 5,165 (36.8)
Congenital anomalies 1,926 (24.3) 1,630 (26.7) 3,556 (25.3)
Symptoms, signs and ill-defined conditions 426 (5.4) 332 (5.4) 758 (5.4)
External causes of injury and poisoning 651 (8.2) 387 (6.3) 1,038 (7.4)
aMost recent vaccination: none.
bMost recent vaccinations: DTaP(−HBV)-IPV/Hib and pneumococcal vaccination.
cMost recent vaccinations: MMR and meningococcal C vaccination (only after September 2002).
dMost recent vaccination: DTaP-IPV booster vaccination.
eMost recent vaccinations: DT-IPV booster and MMR booster vaccination.
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Childhood mortality in the Netherlands was very low
and declined further over the period from 2000–2011.
Mortality from natural causes between birth and 12 years
of age was consistently lower among girls than among
boys. We observed no significant difference in the
female-to-male IRR in DTP-IPV- and MMR ±MenC-
eligible children with respect to the last scheduled
vaccination.
A major strength of this study is that near complete
mortality data were obtained for a long time period from
the national registry for causes of death and included
the entire Dutch population. However, this study also
has some limitations. We could not verify the individualvaccination status of the children and assumed that vac-
cinations were given as scheduled. A recent study ob-
served that 82% of the vaccinated population received
the first DTaP-IPV within 9 weeks of age (<70 days) [20].
The median age at vaccination was 62 days (5th to 95th
percentile 51–81 days). Vaccination coverage (personal
communication A. van Lier) and delay in vaccination [20]
in the Netherlands does not differ by sex. However, delay
in vaccination may have resulted in an underestimation of
the effect of the last received vaccination on mortality.
Furthermore, changes in the vaccination schedule were
made during the study period. Haemophilus influenzae
type b and hepatitis b components were added to the
DTP-IPV vaccine in 2003 and 2011, respectively and in
Table 4 Crude mortality rates due to natural causes in children with respect to gender and age group, from 2000–2011,
and adjusted incidence rate ratios (IRR) for girls compared with boys










(N = 7145) Years (95% CI) (N = 5605) Years (95% CI)
0-1 months 4578 32.1 (31.2-33.1) 3555 26.2 (25.3-27.0) 0.81 (0.78-0.85)
2-13 months 1035 4.6 (4.3-4.8) 797 3.7 (3.4-3.9) 0.81 (0.74-0.89)
14 months – 3 years 680 1.4 (1.3-1.5) 551 1.2 (1.1-1.3) 0.85 (0.76-0.95) 0.493b
4-8 years 552 0.7 (0.7-0.8) 441 0.6 (0.5-0.7) 0.84 (0.74-0.95) 0.868c
9-11 years 300 0.6 (0.5-0.6) 261 0.5 (0.5-0.6) 0.91 (0.77-1.07)
0.723d
aAdjusted for calendar year.
bp-value for interaction (df = 1) between age group and gender for 14 months – 3 years of age versus 2–14 months of age.
cp-value for interaction (df = 1) between age group and gender for 4–8 years of age versus 14 months – 3 years of age.
dp-value for interaction (df = 4) between age group and gender for all age groups.
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taneously. In September 2002 vaccination against men-
ingococcal C was introduced for children 14 months of
age together with a catch-up campaign for children up
to 19 years of age. This could possibly have interfered with
the potential effect of MMR vaccination and therefore
sensitivity analysis was done to compare the periods be-
fore and from September 2002 onwards. This analysis did
not change our conclusions. Additionally, children with
parents originating from tuberculosis endemic countries
are offered vaccination with the BCG vaccine in addition
to vaccinations through the NIP. BCG vaccination couldFigure 2 Female-to-male incidence rate ratios up to 12 years of age.
intervals, for girls compared to boys for mortality due to natural causes, fropotentially interfere with the results of the study. To ex-
clude this, we conducted a sensitivity analysis including
indigenous Dutch children only, which resulted in similar
findings. Also, we conducted sensitivity analysis for nat-
ural causes of death except for pregnancy, childbirth
and perinatal complications and congenital abnormal-
ities to exclude causes of death which were not related
to immune system complications. This analysis did also
not change our conclusion. Finally, analysis for children
who died due to infectious or parasitic diseases only
also has not led to other results, although numbers were
low.Plot of crude incidence rate ratios (IRR), including 95% confidence
m 2000–2011, by month of age up to 12 years.
Table 5 Incidence rate ratios (IRR) for girls compared with boys for indigenous Dutch children only, for the periods before and from September 2002 onwards,
and for natural causes of death other than complications of pregnancy, childbirth, perinatal period and congenital abnormalities































0-1 months 0.80 (0.76-0.84) 0.81 (0.74-0.88) 0.82 (0.78-0.86) 0.97 (0.82-1.15) 1.13 (0.67-1.90)
2-13 months 0.78 (0.70-0.87) 0.86 (0.73-1.02) 0.79 (0.71-0.88) 0.74 (0.65-0.84) 0.79 (0.55-1.13)
14 months – 3 years 0.79 (0.69-0.90) 0.882b 0.81 (0.66-0.99) 0.637b 0.87 (0.76-0.99) 0.266b 0.82 (0.73-0.93) 0.789b 0.90 (0.63-1.27) 0.621b
4-8 years 0.83 (0.72-0.96) 0.637c 0.75 (0.59-0.96) 0.652c 0.87 (0.75-1.01) 0.973c 0.85 (0.74-0.97) 0.217c 0.95 (0.52-1.75) 0.863c
9-11 years 0.92 (0.75-1.11) 0.72 (0.52-0.98) 1.00 (0.82-1.21) 0.89 (0.75-1.06) 0.71 (0.33-1.54)
0.673d 0.835d 0.248d 0.112d 0.817d
aAdjusted for calendar year.
bp-value for interaction (df = 1) between age group and gender for 14 months – 3 years of age versus 2–14 months of age.
cp-value for interaction (df = 1) between age group and gender for 4–8 years of age versus 14 months – 3 years of age.
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boys following DTP-IPV vaccination in conjunction with
a significant declining female-to-male IRR after measles
vaccination as reported previously in countries with high
childhood mortality [6,10,13-15,17]. In our study, female-
to-male IRRs were less than 1 for all age groups and did
not differ between age groups. A possible explanation for
the different findings could be the major difference in
populations and in setting between our study and previous
studies. Our study was conducted in a high-income coun-
try with low mortality among children, whereas the other
studies were conducted in low-income settings with high
childhood mortality. In the latter setting, healthcare is less
accessible, infectious disease burden from non-vaccine
preventable diseases can be significantly higher, and child-
hood nutrition might be less balanced. These conditions
may exhibit a differential impact on girls versus boys or
on vaccinated versus unvaccinated children, as reasons for
non-vaccination are unlikely to be random, leading to a
potential selection bias [21]. Furthermore, it might be
more difficult to collect complete validated data on child-
hood mortality as well as detailed and reliable information
on vaccination status, leading to survival bias [8,21,22]. In
addition, the non-specific effects of vaccination are less
likely to influence overall mortality in high-income set-
tings because of the low prevalence of infectious diseases
and the small number of children who die due to infec-
tious diseases. It would be more sensitive to assess these
non-specific effects on morbidity. In Denmark, a high-
income county, receipt of the MMR vaccine versus the
DTaP-IPV-Hib vaccine as the most recent vaccine was
found to be associated with a lower rate of hospital admis-
sions due to infections [23]. However, no difference was
observed between boys and girls, which indicate that non-
specific effects are not necessarily sex-differential.
Conclusions
In conclusion, we did not find indications for sex-
differential non-specific effects on mortality related to
the last scheduled vaccination in DTP-IPV- and MMR ±
MenC-eligible children in the Netherlands. These study
results are important for public health policies. Ongoing
evaluation of specific and potential non-specific effects
of vaccinations on mortality and morbidity in high-
income countries is needed to guide policy, to provide
accurate information of the benefits and risks of vaccin-
ation and to maintain public trust in public health inter-
ventions, such as vaccination.
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